Search Results - "Buys, Andy"

Stereotactic Ablative Radiation Therapy to All Lesions in Patients With Oligometastatic Cancers: A Phase 1 Dose-Escalation Trial by Mercier, Carole, Claessens, Michaël, Buys, MSc, Andy, Gryshkevych, Sergii, Billiet, Charlotte, Joye, Ines, Van Laere, Steven, Vermeulen, Peter, Meijnders, Paul, Löfman, Fredrik, Poortmans, Philip, Dirix, Luc, Verellen, Dirk, Dirix, Piet

“…Increasing evidence suggests that patients with a limited number of metastases benefit from SABR to all lesions. However, the optimal dose and fractionation…”
Get full text

Circulating tumor cell detection: A prospective comparison between CellSearch® and RareCyte® platforms in patients with progressive metastatic breast cancer by Dirix, Luc, Buys, Andy, Oeyen, Steffy, Peeters, Dieter, Liègeois, Vincent, Prové, Annemie, Rondas, Dieter, Vervoort, Liesbet, Mariën, Véronique, Laere, Steven Van, Vermeulen, Peter

“…Purpose Circulating tumor cells (CTCs) are prognostic in patients with breast cancer. Several technical platforms exist for their enumeration and…”
Get full text

Abstract OT3-18-02: A comparative study of two detection platforms of circulating tumour cells in patients with metastatic breast cancer by Peeters, Dieter, Buys, Andy, Ledegen, Hannah, Moehlig, Kathlyn, Oeyen, Steffi, Rondas, Dieter, De Beukelaer, Alexia, Van Laere, Steven, Vervoort, Liesbet, Vermeulen, Peter, Ung, Christopher, Kockx, Mark, Dirix, Luc

“…Abstract Background: The enumeration of circulating tumour cells (CTCs) using the FDA-cleared CellSearch system has repeatedly been proven to bear prognostic…”
Get full text

Coagulation/fibrinolysis and circulating tumor cells in patients with advanced breast cancer by Dirix, Luc Y., Oeyen, Steffi, Buys, Andy, Liégois, Vincent, Prové, Annemie, Van De Mooter, Tom, Van Laere, Steven, Vermeulen, Peter B.

“…Purpose To evaluate the relationship between circulating tumor cells (CTCs) and standard coagulation tests in both a discovery and a validation cohort of…”
Get full text

Automated enumeration and phenotypic characterization of CTCs and tdEVs in patients with metastatic castration resistant prostate cancer by Oeyen, Steffi, Liégeois, Vincent, De Laere, Bram, Buys, Andy, Strijbos, Michiel, Dirix, Piet, Meijnders, Paul, Vermeulen, Peter, Van Laere, Steven, Dirix, Luc

“…Background Although most patients with metastatic castration-resistant prostate cancer (mCRPC) initially benefit from treatment with androgen receptor…”
Get full text